Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

citalopram

- PMLiVE

Schultz takes Lundbeck helm after leaving Novo Nordisk

Former executive left Danish firm just days ago

Bristol-Myers Squibb (BMS) building

BMS shines in Q1, but Abilify generics cast a long shadow

Revenue up 6% but Ablify’s contribution likely to drop due to competition

- PMLiVE

Teva offers $40bn for Mylan as Perrigo backs away

Generic drug industry could be shaken up if deals go through

Teva Pharma logo

Teva slapped with $512m fine on pay-for-delay deal

Israeli firm pays out to settle claims it hindered use of generic Provigil

Daiichi Sankyo logo

Daiichi Sankyo offloads stake in India’s Sun Pharma

Japanese firm wants to shed its share of the generic Indian drugmaker

- PMLiVE

Rise of generics will curb France’s pharma growth

Generics are set to take a serious bite out of the market as a cash-strapped government pushes for cost controls

- PMLiVE

First generic version of Teva’s Copaxone cleared by FDA

Will be marketed as Glatopa by Momenta and Novartis’ Sandoz subsidiary

- PMLiVE

Gilead under fire for Sovaldi anti-diversion policy

Accused as generic versions of the drug start to reach the market

Eli Lilly HQ

German court overturns patent on Lilly blockbuster Alimta

Verdict means Actavis can launch generic after December

- PMLiVE

Brintellix first antidepressant with cognition claim in Europe

Trial found it performed better than Lilly’s rival Cymbalta

France flag

French pharma growth restricted by generics

New analysis finds country’s market value will grow only modestly in the coming years

- PMLiVE

ViiV maintains top spot in reputation survey

But former top-ranked Gilead slides down in PatientView poll of patient groups

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links